Drug intelligence / Profile preview

PDL1-CAR-TNK

Development stage: Discontinued
Lead developer: Sorrento Therapeutics
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies

Overview

**PDL1-CAR-TNK** is a discontinued preclinical, allogeneic CAR-NK cell-therapy candidate intended for cancer. It was part of Sorrento Therapeutics and Conkwest's CAR.TNK program, which combined an engineered chimeric antigen receptor with Conkwest's NK-92-derived Neukoplast natural-killer cell platform. The CAR was designed to recognize programmed death-ligand 1 on tumor cells, directing NK-cell-mediated cytotoxicity against PD-L1-expressing malignancies. Sorrento publicly identified PD-L1 CAR.TNK as a preclinical CAR.TNK program for hematologic malignancies and solid tumors. ([sec.gov](https://www.sec.gov/Archives/edgar/data/850261/000119312514448802/d841061dex991.htm))

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on PDL1-CAR-TNK.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PDL1-CAR-TNK.

Explore the full profile